Citigroup’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-43
| Closed | -$1.55K | – | 5598 |
|
|
2024
Q4 | $1.55K | Hold |
43
| – | – | ﹤0.01% | 5561 |
|
|
2024
Q3 | $1.28K | Hold |
43
| – | – | ﹤0.01% | 5437 |
|
|
2024
Q2 | $1.42K | Hold |
43
| – | – | ﹤0.01% | 5359 |
|
|
2024
Q1 | $1.49K | Hold |
43
| – | – | ﹤0.01% | 5407 |
|
|
2023
Q4 | $1.54K | Hold |
43
| – | – | ﹤0.01% | 5443 |
|
|
2023
Q3 | $1.91K | Hold |
43
| – | – | ﹤0.01% | 4974 |
|
|
2023
Q2 | $1.77K | Hold |
43
| – | – | ﹤0.01% | 5302 |
|
|
2023
Q1 | $1.73K | Hold |
43
| – | – | ﹤0.01% | 5106 |
|
|
2022
Q4 | $1.67K | Hold |
43
| – | – | ﹤0.01% | 5292 |
|
|
2022
Q3 | $2K | Hold |
43
| – | – | ﹤0.01% | 5476 |
|
|
2022
Q2 | $2K | Hold |
43
| – | – | ﹤0.01% | 5856 |
|
|
2022
Q1 | $2K | Hold |
43
| – | – | ﹤0.01% | 6042 |
|
|
2021
Q4 | $2K | Hold |
43
| – | – | ﹤0.01% | 5728 |
|
|
2021
Q3 | $2K | Hold |
43
| – | – | ﹤0.01% | 5659 |
|
|
2021
Q2 | $2K | Hold |
43
| – | – | ﹤0.01% | 5964 |
|
|
2021
Q1 | $2K | Hold |
43
| – | – | ﹤0.01% | 6035 |
|
|
2020
Q4 | $2K | Hold |
43
| – | – | ﹤0.01% | 7226 |
|
|
2020
Q3 | $3K | Hold |
43
| – | – | ﹤0.01% | 7194 |
|
|
2020
Q2 | $3K | Hold |
43
| – | – | ﹤0.01% | 7344 |
|
|
2020
Q1 | $5K | Hold |
43
| – | – | ﹤0.01% | 7257 |
|
|
2019
Q4 | $5K | Hold |
43
| – | – | ﹤0.01% | 7381 |
|
|
2019
Q3 | $7K | Hold |
43
| – | – | ﹤0.01% | 7205 |
|
|
2019
Q2 | $6K | Hold |
43
| – | – | ﹤0.01% | 7427 |
|
|
2019
Q1 | $6K | Hold |
43
| – | – | ﹤0.01% | 7367 |
|
|
2018
Q4 | $8K | Sell |
43
-137
| -76% | -$22.1K | ﹤0.01% | 7228 |
|
|
2018
Q3 | $23K | Hold |
180
| – | – | ﹤0.01% | 7008 |
|
|
2018
Q2 | $28K | Sell |
180
-13
| -7% | -$2.16K | ﹤0.01% | 6730 |
|
|
2018
Q1 | $33K | Sell |
193
-62
| -24% | -$9.95K | ﹤0.01% | 6433 |
|
|
2017
Q4 | $45K | Buy |
+255
| New | +$45.3K | ﹤0.01% | 6246 |
|
|
2016
Q1 | – | Sell |
-3
| Closed | -$1K | – | 7458 |
|
|
2015
Q4 | $1K | Sell |
3
-69
| -96% | -$17.7K | ﹤0.01% | 7358 |
|
|
2015
Q3 | $22K | Buy |
+72
| New | +$17K | ﹤0.01% | 5960 |
|
Other funds holding BIS
TRCT
Citigroup's BIS Position: Q1 2025 in Review
Citigroup sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q1 2025, closing a stake of 43 shares — an estimated $1.55K sold.
Citigroup first reported a position in BIS in Q3 2015 and held it in 31 quarters. The position peaked at $45K in Q4 2017. 4 funds tracked by Wall St. Rank hold BIS as of Q1 2025.
- Citigroup reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q1 2025 after selling out during the quarter.
- Citigroup sold 43 ProShares UltraShort NASDAQ Biotechnology shares in Q1 2025, an estimated $1.55K.
- Citigroup first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q3 2015 and held it in 31 quarters.
- Citigroup's ProShares UltraShort NASDAQ Biotechnology position peaked at $45K in Q4 2017.
- 4 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q1 2025.
Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.